Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Total Liabilities (2016 - 2025)

Traws Pharma's Total Liabilities history spans 14 years, with the latest figure at $11.2 million for Q4 2025.

  • Quarterly results put Total Liabilities at $11.2 million for Q4 2025, down 80.13% from a year ago — trailing twelve months through Dec 2025 was $11.2 million (down 80.13% YoY), and the annual figure for FY2025 was $11.2 million, down 80.13%.
  • Total Liabilities for Q4 2025 was $11.2 million at Traws Pharma, up from $7.9 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $56.6 million in Q4 2024 to a low of $7.4 million in Q2 2025.
  • The 5-year median for Total Liabilities is $11.3 million (2021), against an average of $13.2 million.
  • The sharpest move saw Total Liabilities surged 371.17% in 2024, then crashed 80.13% in 2025.
  • Year by year, Total Liabilities stood at $9.4 million in 2021, then rose by 18.22% to $11.1 million in 2022, then increased by 8.57% to $12.0 million in 2023, then skyrocketed by 371.17% to $56.6 million in 2024, then crashed by 80.13% to $11.2 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $11.2 million, $7.9 million, and $7.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.